SCHEMBL4966366

SCHEMBL4966366

CCOC(=O)CC(OC)OCC

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGAM O43451 1/20 0.44
GAA P10253 1/20 0.44
SI P14410 1/20 0.44
MGAM2 Q2M2H8 1/20 0.44
ALDH1A1 P00352 7/20 0.42
ALOX15 P16050 3/20 0.42
TSHR P16473 3/20 0.42
CYP3A4 P08684 2/20 0.42
TDP1 Q9NUW8 1/20 0.42
TRPA1 O75762 1/20 0.41
HSD17B10 Q99714 2/20 0.41
CHRM1 P11229 1/20 0.41
ADORA1 P30542 1/20 0.41
CYP1A2 P05177 1/20 0.36
LMNA P02545 1/20 0.36
SOAT1 P35610 1/20 0.34
ELANE P08246 1/20 0.34
CYP2D6 P10635 1/20 0.34
KDM4E B2RXH2 1/20 0.34
HTT P42858 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL204730 0.89 GAA (0.50) MGAMGAASIMGAM2ALDH1A1
SCHEMBL1873215 0.89 GAA (0.50) MGAMGAASIMGAM2ALDH1A1
SCHEMBL13211935 0.85 TSHR (0.39) MGAMGAASIMGAM2ALDH1A1
SCHEMBL29077537 0.83 NAAA (0.47) ALDH1A1TSHRTDP1L3MBTL1
SCHEMBL28642500 0.77 ALDH1A1 (0.39) MGAMGAASIMGAM2ALDH1A1
SCHEMBL8574175 0.77 MGAM (0.46) MGAMGAASIMGAM2ALDH1A1
SCHEMBL28746748 0.77 ALOX15 (0.36) ALOX15L3MBTL1
SCHEMBL1881682 0.77 NAAA (0.38) MGAMGAASIMGAM2ALDH1A1
SCHEMBL2909876 0.76 MGAM (0.41) MGAMGAASIMGAM2ALDH1A1
SCHEMBL8076573 0.76 MGAM (0.41) MGAMGAASIMGAM2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159543-A1 ANTHELMINTIC PYRROLOPYRIDAZINE COMPOUNDS BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) 2023-05-25 US disclosed
US-20080306096-A1 Quinazoline Derivatives, Process for Their Preparation and Their Use as Anti-Cancer Agents ASTRAZENECA AB (SE) 2008-12-11 US disclosed
EP-1966159-A2 CHEMICAL COMPOUNDS AstraZeneca AB (SE) 2008-09-10 EP disclosed
WO-2007071963-A2 QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTI-CANCER AGENTS ASTRAZENECA AB (SE) 2007-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306096-A1 Quinazoline Derivatives, Process for Their Preparation and Their Use as Anti-Cancer Agents BRAF, RAF1, NRAS MGAM 1292/4885GAA 2471/4885SI 1635/4885
US-20230159543-A1 ANTHELMINTIC PYRROLOPYRIDAZINE COMPOUNDS IL5, EPX, MPO MGAM 3027/4885GAA 2745/4885SI 558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.